The details of the trial are at:https://www.clinicaltrials.gov/ct2/show/NCT03401073?recrs=abdefm&cond=neuropathy&intr=immunoglobulin&cntry=US&state=US%3AMA&rank=1

In brief, it is to see whether IVIG is effective in lowering pain in patients who have all four of the following:
1. Skin biopsy that shows small fiber neuropathy
2. No known cause of the neuropathy; also termed idiopathic
3. Pain of more than 4 on a scale of 1 to 10
4. Positive blood test (that they would do when you go in to be evaluated) that shows one of two newly identified antobodies against nerve cells
The trial is being done at Beth Israel Hospital in Boston. They will enroll 20 patients, half of which will get placebo and the other half IVIG. The principal investigator is Dr. Christopher Gibbons. If you are interested, contact Sharika Rajan MD at either srajan@bidmc.harvard.edu, or call the main BI number at 617-667-8000 and ask for Dr. Rajan. NOTE: the contact phone number given on the website link above for Dr. Rajan is not a working phone number.